Browse Category

NASDAQ:VMAR News 17 December 2025

Vision Marine Technologies Stock (NASDAQ: VMAR) Surges on Massive Volume as SEC Filing Details a Potential $8M Share Offering (Dec. 17, 2025)

Vision Marine Technologies Stock (NASDAQ: VMAR) Surges on Massive Volume as SEC Filing Details a Potential $8M Share Offering (Dec. 17, 2025)

Dec. 17, 2025 — Vision Marine Technologies Inc. (NASDAQ: VMAR) is back on traders’ radar after a dramatic spike in price and volume, followed by renewed debate over dilution risk tied to a freshly amended securities filing. The move has been eye-catching even by micro-cap standards: intraday swings, unusually heavy participation, and the kind of “what just happened?” tape action that often appears when momentum collides with financing mechanics. Below is what’s driving Vision Marine Technologies stock today, what the company’s filing actually says, and what investors are watching next. VMAR stock today: explosive volume, sharp swings, and volatility signals

Stock Market Today

Costco stock price retakes $1,000 — what traders are watching before Monday

Costco stock price retakes $1,000 — what traders are watching before Monday

7 February 2026
Costco closed Friday up 1.2% at $1,001.16, regaining the $1,000 level as about 2.36 million shares changed hands. January net sales rose 9.3% to $21.33 billion, with comparable sales up 7.1% and online sales surging 34.4%. Wells Fargo raised its price target to $950, maintaining a neutral rating. The next earnings call is set for March 5.
Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

Johnson & Johnson stock price: What to watch after talc-case law firm ouster and new AFib data

7 February 2026
Johnson & Johnson shares rose 0.9% to $239.99 Friday after a New Jersey appeals court disqualified Beasley Allen from state talc cases, citing improper coordination with a former J&J attorney. The ruling affects about 3,600 state lawsuits, while a related federal motion is pending. J&J also reported early 12-month pilot data for its investigational AFib device at a cardiology meeting.
Go toTop